An open source pharma roadmap

• Manica Balasegaram,

  Affiliation Médecins Sans Frontières, Geneva, Switzerland

  ⨯
• Peter Kolb,

  Affiliation Department of Pharmaceutical Chemistry, Philipps-University Marburg, Marburg, Germany

  ⨯
• John McKew,

  Current address: Lumo Pharma, Austin, Texas, United States of America

  Affiliation National Institutes of Health, National Center for Advancing Translational Sciences (NCATS), Bethesda, Maryland, United States of America

  ⨯
• Jaykumar Menon,

  Affiliation McGill University Institute for the Study of International Development, Montreal, Canada

  http://orcid.org/0000-0002-7118-7744

  ⨯
• Piero Olliaro,

  Affiliations UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland, Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Tomasz Sablinski,

  Affiliation Transparency Life Sciences, New York, New York, United States of America

  ⨯
• Zakir Thomas,

  Current address: Directorate of Risk Assessment, Government of India, New Delhi, India

  Affiliation Open Source Drug Discovery, Council of Scientific and Industrial Research (CSIR), New Delhi, India

  http://orcid.org/0000-0001-9296-5130

  ⨯
• Matthew H. Todd ,

  * E-mail: matthew.todd@sydney.edu.au

  Affiliation School of Chemistry, The University of Sydney, Sydney, Australia

  http://orcid.org/0000-0001-7096-4751

  ⨯
• Els Torreele,

  Affiliation Public Health Program, Open Society Foundations, New York, New York, United States of America

  ⨯
• John Wilbanks

  Affiliation Sage Bionetworks, Seattle, Washington, United States of America

  http://orcid.org/0000-0002-4510-0385

  ⨯